(NASDAQ: KNSA) Kiniksa Pharmaceuticals International's forecast annual revenue growth rate of 19.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Kiniksa Pharmaceuticals International's revenue in 2026 is $840,848,000.On average, 10 Wall Street analysts forecast KNSA's revenue for 2026 to be $78,492,157,078, with the lowest KNSA revenue forecast at $71,363,103,010, and the highest KNSA revenue forecast at $81,769,165,624. On average, 10 Wall Street analysts forecast KNSA's revenue for 2027 to be $96,671,752,107, with the lowest KNSA revenue forecast at $85,202,222,196, and the highest KNSA revenue forecast at $110,560,026,421.
In 2028, KNSA is forecast to generate $110,482,002,408 in revenue, with the lowest revenue forecast at $93,316,719,548 and the highest revenue forecast at $128,817,645,463.